GLAXO - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.4
| Stock Code | GLAXO | Market Cap | 40,764 Cr. | Current Price | 2,406 ₹ | High / Low | 3,516 ₹ |
| Stock P/E | 43.1 | Book Value | 101 ₹ | Dividend Yield | 1.74 % | ROCE | 62.6 % |
| ROE | 46.4 % | Face Value | 10.0 ₹ | DMA 50 | 2,457 ₹ | DMA 200 | 2,631 ₹ |
| Chg in FII Hold | -0.16 % | Chg in DII Hold | -0.05 % | PAT Qtr | 253 Cr. | PAT Prev Qtr | 205 Cr. |
| RSI | 49.7 | MACD | -14.8 | Volume | 38,120 | Avg Vol 1Wk | 69,846 |
| Low price | 1,960 ₹ | High price | 3,516 ₹ | PEG Ratio | -2.17 | Debt to equity | 0.02 |
| 52w Index | 28.7 % | Qtr Profit Var | 3.15 % | EPS | 56.0 ₹ | Industry PE | 29.1 |
📊 Analysis: GLAXO is trading at ₹2,406, slightly below its 50 DMA (₹2,457) and 200 DMA (₹2,631), showing near-term weakness. RSI at 49.7 indicates neutral momentum, while MACD at -14.8 suggests bearish undertone. Intraday volume (38,120) is below the 1-week average (69,846), limiting strong intraday moves. Valuation is high with a P/E of 43.1 compared to industry P/E of 29.1, suggesting overvaluation risk despite strong fundamentals.
💡 Optimal Buy Price: ₹2,380–2,400 (near support zone).
🎯 Profit-Taking Levels: ₹2,440–2,460 (short-term resistance near 50 DMA).
🛡️ Stop-Loss: ₹2,360 (below support).
⏱️ If Already Holding: Exit intraday if price fails to sustain above ₹2,400 or if MACD continues negative with weakening momentum. Consider booking profits near ₹2,440–2,460 if price action stalls and volume remains subdued.
✅ Positive
- Strong ROCE (62.6%) and ROE (46.4%) reflect excellent capital efficiency.
- Quarterly PAT growth from ₹205 Cr. to ₹253 Cr. shows earnings improvement.
- Dividend yield of 1.74% adds income stability.
- EPS of ₹56 supports earnings visibility.
⚠️ Limitation
- Trading below both 50 DMA and 200 DMA indicates weak technical setup.
- High P/E of 43.1 compared to industry average of 29.1 suggests overvaluation.
- PEG ratio of -2.17 signals poor growth alignment with valuation.
- Intraday volume weaker than average, reducing trading opportunities.
📉 Company Negative News
- Decline in FII (-0.16%) and DII (-0.05%) holdings signals reduced institutional confidence.
📈 Company Positive News
- Quarterly PAT growth of 3.15% shows steady improvement.
- Strong fundamentals with high ROCE and ROE support long-term outlook.
🏭 Industry
- Industry P/E at 29.1 is lower than GLAXO’s 43.1, highlighting relative overvaluation.
- Pharmaceutical sector demand remains resilient with defensive characteristics.
🔎 Conclusion
GLAXO shows limited intraday potential due to weak technicals and subdued volume. While fundamentals remain strong, overvaluation and bearish MACD suggest caution. Suitable only for disciplined intraday traders with tight stop-loss and modest profit targets around ₹2,440–2,460.